Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
The Formulation & Technology Centre intends to function as a technology storefront, offering advanced formulation and processing solutions to address the growing demand for complex drug formulations
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Subscribe To Our Newsletter & Stay Updated
_256_384.JPG)
